• The 10th anniversary of Avistone Biotechnology

• The NDA application of Vebreltinib has been officially accepted by the China CDE and approved for priority review

• Vebreltinib received orphan drug designation from the U.S. FDA

• The patient enrollment was formally completed for the glioma indication of Vebreltinib

• The discovery of the key driver of the malignant progression of glioma and the development and application of new small molecule inhibitors of Vebreltinib won the first prize of "Entrepreneurship Award" issued by the China Invention Association

• The US IND application of andatinib (PLB1004) is officially opened, which is a key step to open up the global market

• The ANS01 program identified candidate compounds that address the activation circle resistance of type Ib c-Met inhibitors, as well as common Met gene abnormalities, including exon 14 skipping mutations and gene amplification

Vebreltinib received recognition for breakthrough therapy on March 2021 from Drug Approval Center under National Medical Products Administration, with tentative indication being non-small cell lung cancer with c-MET expressed region 14 mutation; patent approval for Andatinib (PLB1004) compound; Avistone completed Series A funding, raising more than $200 million.

Clinical trial approval and launch of clinical trial for Andatinib (PLB1004).

Launch of Vebreltinib for Phases II critical registration for clinical trials for non-small cell lung cancer indication; IND filing for Andatinib (PLB1004).

Inception of Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.; launch of Vebreltinib GBM Phases II/III critical registration for clinical trials; patent approved for Vebreltinib precision treatment for glioma; operating mechanism and results of the Phase I clinical trial for Vebreltinib treatment for glioma published on the top international medical publication "Cell"; precision treatment of Vebreltinib for glioma named "China's Top 10 Advances in Life Sciences in 2018" by China Association for Science and Technology.

First example of patient with non-small cell lung cancer indication included in Vebreltinib group; first example of patient with glioma indication included in Vebreltinib group; major project support for Vebreltinib under "Major Drug Innovation of the Thirteenth Five-Year Plan".

Clinical trial officially commenced for Vebreltinib following approval. Dr. Shi Hepeng nominated for "Beijing Leading Innovation & Entrepreneurial Talent Support Plan" by Beijing Municipal Human Resources and Social Security Bureau.

Dr. Shi Hepeng named "Beijing 100 Leading S & T Talents Development Project" by Beijing Municipal Science and Technology Commission.

Patent approval and IND filing for Vebreltinib.

Inception of Beijing Purun'ao Biotechnology Co.,Ltd.